12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

BioThrax regulatory update

FDA approved an sBLA from Emergent to change the administration schedule of BioThrax anthrax vaccine to a 3-dose primary series of intramuscular injections at 0, 1 and...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >